Search
Search
Eyewire News: The Podcast
07.29.26
The CEO of Outlook Therapeutics discusses the FDA approval of wet AMD drug Lytenava; Roche receives a major boost in its efforts to commercialize wet AMD treatment Susvimo in Europe; and Glaukos reaches a milestone in its pivotal clinical study of the Preserflo MicroShunt. Learn more about your ad choices. Visit megaphone.fm/adchoices
View full description +
Subscribe
07.22.26
PRIMA Retinal Implant Launched in EUShow More
